➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Mallinckrodt
McKinsey
Baxter
AstraZeneca

Last Updated: September 19, 2020

DrugPatentWatch Database Preview

Patent: 8,460,933

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,460,933
Title:Expression system incorporating a capsid promoter sequence as an enhancer
Abstract: The invention provides a method for enhancing expression of a transgene in a host cell, which includes the steps of inserting a capsid promoter element (Pcap), or a sequence comprising the reverse complement of the capsid promoter element (PcapR), into a mammalian expression cassette upstream (5\') of a cytomegalovirus immediate/early enhancer/promoter region (Pcmv); inserting the transgene into the expression cassette downstream (3\') of the cytomegalovirus immediate/early enhancer/promoter region; inserting a vector containing the expression cassette into the host organism; and causing expression of the transgene. The capsid promoter element (Pcap) is typically from a circovirus, parvovirus or anellovirus. The transgene is typically expressed at a higher level than when expressed by a vector containing the expression cassette without the transcriptional control element. An expression cassette, vector, DNA vaccine, pharmaceutical composition and method of treatment are also claimed.
Inventor(s): Rybicki; Edward Peter (Cape Town, ZA), Tanzer; Fiona Lesley (Cape Town, ZA)
Assignee: South African Medical Research Council (Cape Town, ZA) University of Cape Town (Cape Town, ZA)
Application Number:12/084,728
Patent Claims:see list of patent claims

Details for Patent 8,460,933

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial South African Medical Research Council (Cape Town, ZA) University of Cape Town (Cape Town, ZA) 2025-11-08 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial South African Medical Research Council (Cape Town, ZA) University of Cape Town (Cape Town, ZA) 2025-11-08 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial South African Medical Research Council (Cape Town, ZA) University of Cape Town (Cape Town, ZA) 2025-11-08 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Harvard Business School
Colorcon
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.